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Abstract 
Pre-eclampsia is the most common pregnancy complication that can be fatal for the 
mother and fetus. There is no cure nor known cause of disease, but symptoms are treatable. Pre-
eclampsia causes 13 out of 100 maternal deaths due to pregnancy complications worldwide. Pre-
eclampsia is defined by high blood pressure and high protein urine content 20 weeks into 
pregnancy. The objective of this study is to investigate the relationships between toxic metals 
and key signaling pathways that are associated with placental health. This study utilized 40 
samples provided through a collaboration with UNC hospital. The samples were tested for metals 
levels and both gene and protein expression. We found that there is a positive, significant 
association between cadmium and zinc in pre-eclampsia cases. Additionally, in thyroid hormone 
receptor alpha (THRA) protein expression was significantly higher in cases than in controls.  The 
placental zinc levels were also significantly lower in pre-eclampsia cases. These results agree 
with several other findings that have suggested the influence of thyroid hormone regulation on 
placenta placement and pre-eclampsia development. This suggests that relationships between 
metals and thyroid signaling may impact the development of pre-eclampsia. Based on these 
results, further studies can be done to understand the role of toxic metals in the pathogenesis of 
pre-eclampsia in terms of thyroid hormone dysfunction and placental formation errors. 
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Introduction 
 We hypothesized that maternal exposure to toxic metals is associated with thyroid 
hormone signaling disruption and pre-eclampsia. In order to understand this relationship, we 
conducted a pilot study at UNC Hospitals to investigate the relationships and their connections to 
pre-eclampsia. Pre-eclampsia is a pregnancy complication that is characterized by high blood 
pressure and high urine protein content after 20 weeks of pregnancy. It is a potentially a life-
threatening condition to both the mother and the fetus if the placenta is not removed from the 
body in time. Pre-eclampsia causes 13% of all maternal deaths worldwide and 18% of maternal 
deaths in the United States [1]. Although pre-eclampsia occurs in part because of dysfunction of 
the placenta, the biological causes are still unknown. Several risk factors have been identified 
including obesity, previous history of high blood pressure, and multiple births [2]. It has been 
suggested that the positioning or formation of the placenta, if incorrect, can lead to hypoxia, 
which can induce the increase in protein levels and blood pressure characteristic of pre-
eclampsia [3]. Other suggestive causes include genetic links to thyroid dysfunction that affect 
placental formation [4,5].  
Environmental contaminants such as metals have been suggested to play potential roles in 
the development of pre-eclampsia. Toxic metals such as lead and cadmium are environmental 
pollutants, which pose a serious threat to human health. Humans are exposed through food, 
smoking, occupational hazards, water sources, air, and soil. The average mean for lead and 
cadmium blood levels in pregnant women are 19.80 µg/L and 0.53 µg/L respectively [6,7]. In 
previous studies, toxic metals were associated with several pregnancy complications such as 
reduced birth weight, gestational hypertension, and pre-eclampsia [6,8]. The half-lives for these 
metals in the placenta ranges from several months for lead to decades for cadmium [7,9]. Lead is 
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able to cross the placenta, while the placenta acts as a partial barrier to cadmium so some 
cadmium is prevented from reaching the fetus. Cadmium accumulates in the placenta and has 
been found in umbilical cord blood [6]. Thus, the fetus is exposed to these toxic metals through 
blood exchange and interaction with the placenta [6]. 
Studies on venous blood samples from pregnant women have shown that toxic metals 
such as lead and cadmium are significantly associated with pre-eclampsia [8,10,11]. There are 
various ways that metals can influence placental biology. For example, lead exposure contributes 
to an oxidative stress, which leads to a decrease in placental cell proliferation and cell death [12]. 
This affects the development of the placenta and ultimately leads to endothelial dysfunction 
characteristic in pre-eclampsia [12]. Lead acts more directly on the reproductive system and the 
fetus, whereas cadmium accumulates in placental tissue. Cadmium is commonly found in 
cigarette smoke, but interestingly, cadmium levels in non-smoker and smoker mothers have not 
been found to be significantly different [15]. Studies have shown that cadmium can affect the 
amniotic surface, which affects fetus development and mother-fetus exchange [13]. Little is 
known about the relationship between cadmium, placenta formation, and pre-eclampsia. The 
placental acts as a limited barrier to cadmium which makes it an ideal biomarker for cadmium 
exposure during pregnancy [14].  
Zinc is a key metal in placental development. Studies have found that increased intake of 
zinc supplements can help prevent gestational hypertension, which is characterized by high 
blood pressure when pregnancy begins [10]. However, this has not been shown to prevent pre-
eclampsia, but it does assist in alleviating one of the symptoms of the disorder. Cadmium affects 
the metabolism of several metals including zinc. Cadmium interacts with zinc to result in 
symptoms related to the etio-pathogenesis of eclampsia by impairing the fetoplacental unit and 
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reducing uteroplacental blood flow [15,16]. Cadmium and zinc share similar chemical properties, 
so cadmium can compete for zinc binding sites in the body. There is no regulatory system to 
prevent cadmium toxication, since cadmium binds to zinc binding sites such as metallothionein, 
a storage protein [15]. A buildup in cadmium results in changes in the metabolism of zinc [15]. 
For example, cadmium-methallothionein can be a toxic factor resulting in pre-eclampsia if 
cadmium levels are high [16]. Symptoms of cadmium toxicity closely resemble those of pre-
eclampsia including high protein content in urine and high blood pressure [16] 
Another potential mode of action by metals that is influential in preeclampsia is thyroid 
hormone regulation. Thyroid hormone regulation is important in development of the fetus. 
Progesterone acts on the growth and development of uterine cells for the implantation of embryo 
and formation of the placenta. It does this in part by binding to a thyroid hormone receptor. 
Failure in this signaling and thus failure of the uterine tissues to develop correctly can lead to 
defective placentation and disorders like preeclampsia [17]. Thyroid Hormone Receptor Alpha 
(THRA) is of specific interest because it is a receptor for the thyroid hormone, thiiodothyronine 
(T3), which has been found to be at low levels during embryonic development [18]. This is due 
to the involvement of diodinase, iodothyronine type 3 (DIO3). This enzyme inactivates the 
thyroid hormone T3. DIO3 is found at high levels in the placenta and the pregnant uterus, which 
proposes the necessity of the inactivation of thyroid hormones during placental formation and 
embryo development [19]. THRA regulates the expression of DIO3 by interacting with T3 [22-
24]. Increased levels of thyroid hormone receptor alpha have been associated with fetal growth 
restriction, an adverse outcome associated with pre-eclampsia [24]. Cadmium exposure has been 
associated with disruption of a thyroid hormone signaling pathway, and cadmium has a 
deleterious effect on thyroid function [20]. Zinc is necessary for the binding of THRA to DNA, 
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and the potential for cadmium to take up zinc binding sites can affect THRA function in relation 
to the binding of thiiodothyronine [16,21]. 
In human protein studies, DIO3 has been shown to deactivate the thyroid hormone, 
triiodothyronine (T3). DIO3 expression is increased by the presence of T3, so they operate in a 
negative feedback loop [18]. The upregulation of T3 is dependent on a binding interaction with 
THRA, which is reflective in the increased expression of THRA during gestation due to the spike 
in T3 [22-24]. Zinc is associated with higher levels of T3 and is needed for THRA activation 
[21,26]. Zinc has similar chemical properties to cadmium, which may explain the interactions 
between cadmium and thyroid hormone regulation [16]. Cadmium interrupts DIO3 function and 
is associated with an increase in T3 levels [27]. Higher frequencies of low T3 levels have been 
associated with pre-eclampsia [25]. 
Therefore, in this pilot study, we look specifically at toxic metals because they have been 
linked to several other pregnancy complications that have symptoms linked to pre-eclampsia. A 
focus is put on cadmium, because it has potential links to deleterious effects on thyroid function. 
Zinc is necessary to facilitate the binding of THRA to DNA, and the competition between zinc 
and cadmium due to chemical similarities can potentially affect THRA function in relation to 
regulation of T3. These factors can combine to result in problems with placental formation and 
other symptoms linked to pre-eclampsia. In order to understand these relationships, we examined 
gene and protein expression in placental samples from a random, pilot cohort from UNC 
Hospitals to examine the relationships between metals, thyroid hormone regulation, and pre-
eclampsia.  
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Material and Methods 
Study Cohort Design 
 The participants in the study were recruited at UNC Hospitals by Dr. Kim Boggess. 
Placenta samples were collected with approval from Human Research Ethics Committees at the 
University of North Carolina and Department of Obstetrics & Gynecology, UNC Hospital. Forty 
samples were collected. Half were from healthy individuals to act as controls, and the other half 
were from severe preeclampsia cases. The placental tissue samples were collected at delivery or 
pregnancy termination and stored in 15 mL sterile conical tissue culture treated tubes.  
Placental Tissue Sample Processing 
 The placental samples were stored in AllProtect Tissue Reagent in order to preserve the 
integrity of the tissue. They were then stored at -80ºC for RNA, small RNA, DNA, and protein 
extraction. Before the samples were processed, they were weighed and transferred to 7mL screw 
capped polyethylene vials. The placental tissue were then digested in 300µL optima grade nitric 
acid with cap loosely attached for 12 to 24 hours at room temperature. After 12-24 hours, the 
samples were gradually heated to 85ºC on a heat block for 24 hours. The samples were then 
cooled to room temperature, and 200µL of concentrated hydrogen peroxide (30%, w/w) was 
added. High-purity deionized water was added to the samples to obtain a final volume of 5 mL.  
Metal Analysis 
Internal standard controls were prepared for analysis of a standard panel of metals (arsenic 
(As), cadmium (Cd), chromium (Cr), lead (Pb), nickel (Ni), selenium (Se), vanadium (V), and zinc 
(Zn)) for the calibration and validation of the standard curves. The determination of total As, Cd, 
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Cr, Ni, Pb, Se, V and Zn content was performed with Agilent Technologies 7500cx inductively 
coupled plasma mass spectrometer (ICP-MS, Bellevue, WA, USA).  
Tissue Microarray (TMA) Construction 
Forty human placental specimens were fixed in 10% buffered formalin and embedded in 
paraffin blocks according to a conventional tissue processing procedure. Tissue blocks were cut 
into 5 thick sections and stained with hematoxylin and eosin (H&E). The H&E slides were used 
to guide the TMA construction. For each specimen 6-1mm tissue cores were removed.  
Protein Expression: Antibodies and Immunohistochemistry (IHC)  
Rabbit polyclonal antibodies against type 3 iodothyronine deiodinase (DIO3; ab102926) 
and thyroid hormone receptor alpha (THRA; ab53729) were purchased from Abcam 
(Cambridge, MA). IHC was carried out in the Bond fully automated slide staining system (Leica 
Microsystems Inc.  Norwell, MA). Slides were de-paraffinized in Bond dewax solution 
(AR9222) and hydrated in Bond wash solution (AR9590). Antigen retrieval for all antibodies 
was performed for 30 min at 100ºC in Bond-epitope retrieval solution 1 (AR9961). To inhibit 
non-specific staining, slides were incubated with serum-free protein block for 10 min 
(DakoCytomation Inc., Carpinteria, CA) prior to the addition of the primary antibody. After 
pretreatment THRA (1:500) was applied for 1h, or DIO3 (1:100) for 2h. Detection of all 
antibodies was performed using the Bond Polymer Refine Detection System (DS9800). Stained 
slides were dehydrated and coverslipped. Positive and negative controls (no primary antibody) 
were included for each antibody. 
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Protein Expression: Imaging and Imaging Analysis  
H&E and IHC stained whole tissue and TMA sections were digitally imaged (20x 
objective) using the Aperio ScanScope XT (Aperio Technologies, Vista, CA). TMA slides were 
de-arrayed to visualize individual cores using TMA Lab (Aperio) and the expression of all 
markers was measured using Aperio image analysis algorithms tuned for each stain. DIO3 and 
THRA were analyzed using Aperio cytoplasmic v2 algorithm and the color deconvolution v9 
algorithm. The intensity score and the percentage of positive stained nuclei obtained with the 
nuclear v9 algorithm at each intensity level were used to calculate the H-score using formula: H-
Score  = (% at 1+) * 1 + (% at 2+) * 2 + (% at 3+) * 3. 
Gene Expression  
Expression of THRa and DIO3 mRNA levels were assessed by qRT-PCR using the 
validated QuantiTect Primer Assay (Qiagen, Valencia, CA). Total RNA was isolated from each 
of the placental samples (n=20 controls, n=20 preeclampsia) using Qiagen Allprep Mini Kits 
(Qiagen, Valencia, CA, USA). The amplification conditions for THRA, DIO3, and BACTIN were 
50OC for 30 min (Reverse transcription step), followed by PCR initial activation step (95OC for 
15 min), 40 cycles of 94OC for 15 sec, 55OC for 30 sec, and 72OC for 30 sec on the Mx3005P 
Real-Time PCR system (Stratagene, La Jolla, CA). All samples (n=3) were analyzed in 
duplicate. Fold changes between controls versus cases groups were calculated based on delta-
delta cycle threshold (ΔΔCt) values and normalized with BACTIN as a housekeeping gene. 
Statistical significance of the transcript levels between controls versus cases were calculated 
using an unpaired t-test, with p<0.05 regarded as statistically significant.  
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Statistical Analysis  
Data were analyzed using the statistical package SAS 9.3 (SAS Institute Inc., Cary, North 
Carolina) and Spotfire 6.0 (TIBCO). Relationships between metals to metals and metals to 
thyroid hormone regulatory proteins (THRA and DIO3) were examined using Spearman’s rank 
correlation and a two-tailed t-test. Student’s t-test was used to compare the mean metal levels in 
case and control placental samples. The relationships between metals (e.g. cadmium and zinc) 
and thyroid hormone-related proteins (e.g. THRA and DIO3 protein expression) were analyzed 
using multivariable regression models adjusting for maternal age, maternal race (non-Hispanic 
black, non-Hispanic white, and other), smoking status (current smoker vs current non-smoker) 
and gestational age (weeks). Statistical significance was established if P<0.05.   
Results 
Study Cohort 
The study cohort collected by Kim Boggess consisted of 40 participants, 20 controls and 20 
cases. The demographics of the participants are shown in Table 1 in the supplemental.  
Metals 
Metals were analyzed by ICP-MS with internal standard controls, and the results are displayed 
on Table 2. The relationship of metals in cases and controls is also shown in the heat map in 
Figure 1. There was a significant difference between zinc levels of the cases and controls. As 
shown in Figure 2, cases have lower levels of zinc. The cadmium levels measured in this study is 
in the lower range compared to previous studies: 4.25 ng/g versus a range of 1.2 to 53 ng/g [32]. 
Additionally, the average zinc levels were in the lower ranges compared to other studies: 
8010.46 ng/g versus a range of 5,300 to 169,100 ng/g [30].  
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Table 2: Metal Analysis Determined in Placental Samples by ICP-MS 
Metal  
Mean+/std, Median, 
(Range) 
Control (ng/g) Case (ng/g) Overall (ng/g) 
Arsenic 1.77+/-1.10, 1.56, 
(0.94-6.20) 
1.84+/-1.70, 1.40, 
(0.95-8.91) 
1.81+/-1.41, 1.46, 
(0.94, 8.91) 
Cadmium 4.41+/-2.74, 3.26, 
(1.01-10.42) 
4.10+/-2.12, 4.31, 
(0.35-8.01) 
4.26+/-2.42, 4.28, 
(0.35-10.42) 
Chromium 32.82+/-14.31, 35.03, 
(11.80-59.97) 
49.12+/-33.11, 
36.04, 
 (14.35-125.46) 
40.97+/-26.50, 35.04, 
(11.80, 125.46) 
Lead 5.15+/-7.47, 2.23, 
(1.27-28.96) 
2.77+/-0.77, 2.70, 
(1.12, 4.32) 
3.96+/-5.37, 2.51, 
(1.12-28.96) 
Nickel  7.86+/-4.71, 6.79, 
(1.66-18.58) 
7.82+/-4.46, 6.39, 
(2.24-18.98) 
7.84+/-4.53, 6.46, 
(1.66-18.98) 
Selenium 261.33+/-40.69, 
263.69, 
 (165.26, 333.34) 
267.89+/-51.51, 
276.34,  
(159.21-351.86) 
264.61+/-45.94, 
269.86,  
(159.21-351.86) 
Vanadium 0.54+/-0.16, 0.52, 
(0.31-0.93) 
0.81+/-0.34, 0.75, 
(0.39-1.64) 
0.67+/-0.30, 0.61, 
(0.31-1.64) 
Zinc 8728.43+/-2543.28, 
7965.58,  
(6431.61-17969.99) 
7292.49+/-1150.34, 
7372.07,  
(5266.23-9191.76) 
8010.46+/-2079.56, 
7814.76,  
(5266.23-17969.99) 
 
Figure 1: Heat Map of Metals in Cases/Controls 
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Figure 2: Zinc in Cases/Controls 
 
Metals to Metals 
Correlation and significance of metal to metal relationships are shown in Table 3 with p-values 
lower than 0.05 indicating significance and correlation (r) values higher than approximately 0.6 
indicating correlation. Based on these standards, there is a significant association and a positive 
correlation between zinc and cadmium. This association is shown in Figure 3, stratified by cases 
and controls.  
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Table 3: Spearman Correlation and p-values for Metals to Metals Relationship in Placenta  
r-value  
(p-value) 
Arsenic Cadmium Chromium Lead Nickel Selenium Vanadium Zinc 
Arsenic 1.00000 0.29925 
(0.0607) 
0.23508 
(0.1442) 
0.23227 
(0.1492) 
-0.1127 
(0.4885) 
0.07223 
(0.6578) 
-0.06116 
(0.7077) 
0.22908 
(0.1551) 
Cadmium 0.29925 
(0.0607) 
1.00000 -0.22833 
(0.1565) 
0.14484 
(0.3725) 
-0.0893 
(0.5837) 
0.42008 
(0.0070) 
-0.00150 
(0.9927) 
0.59644 
(<.0001) 
Chromium 0.23508 
(0.1442) 
-0.22833 
(0.1565) 
1.00000 0.28462 
(0.0751) 
0.14221 
(0.3814) 
-0.19212 
(0.2350) 
0.24090 
(0.1343) 
-0.3084 
(0.0528) 
Lead 0.23227 
(0.1492) 
0.14484 
(0.3725) 
0.28462 
(0.0751) 
1.00000 0.33846 
(0.0327) 
0.00300 
(0.9853) 
0.21782 
(0.1769) 
0.08236 
(0.6134) 
Nickel -0.1128 
(0.4885) 
-0.08931 
(0.5837) 
0.14221 
(0.3814) 
0.33846 
(0.0327) 
1.00000 0.13096 
(0.4206) 
0.35704 
(0.0237) 
0.21932 
(0.1739) 
Selenium 0.07223 
(0.6578) 
0.42008 
(0.0070) 
-0.19212 
(0.2350) 
0.00300 
(0.9853) 
0.13096 
(0.4206) 
1.00000 0.01257 
(0.9386) 
0.49737 
(0.0011) 
Vanadium -0.06116 
(0.7077) 
-0.00150 
(0.9927) 
0.24090 
(0.1343) 
0.21782 
(0.1769) 
0.35704 
(0.0237) 
0.01257 
(0.9386) 
1.00000 -0.0098 
(0.9524) 
Zinc 0.22908 
(0.1551) 
0.59644 
(<.0001) 
-0.30844 
(0.0528) 
0.08236 
(0.6134) 
0.21932 
(0.1739) 
0.49737 
(0.0011) 
-0.00976 
(0.9524) 
1.00000 
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Figure 3: Zinc and Cadmium Correlation Stratified by Cases/Controls 
 
Table 4: Multivariable Regression Analyses of Zinc and Cadmium Levels to Protein Expression 
of Thyroid Hormone Signaling Factors 
 THR DIO3 
Controls Cases Controls Cases 
Cadmium = 0.42 
(-0.99, 1.84)  
= -1.18 
(-4.32, 1.97) 
= -1.7 
(-5.3, 1.9) 
= -3.5 
(-8.1, 1.1) 
Zinc = -0.0005 
(-0.0020, 
0.0010) 
= -0.0021, 
(-0.0083, 0.0041) 
= -0.0010 
(-0.0050, 0.0030) 
= -0.0079 
(-0.017, 0.011) 
 
Thyroid Hormone Regulation 
Protein expression was measured with antibodies and IHC with sample sizes of 20. Gene 
expression was measured with qRT-PCR with a sample size of 3 for preliminary results. There is 
an increase in THRA protein levels and a decrease in Dio3 protein levels in preeclampsia cases, 
which is evident in Figure 4. Figures 5 and 6 show the difference between cases and controls of 
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THRA and DIO3 protein expression at the bottom and gene expression at the top corner for 
comparison. There is a significant increase of THRA protein expression in pre-eclampsia cases, 
and a significant decrease in DIO3 gene expression in pre-eclampsia cases.  
Figure 4: Protein Expression 
 
Figure 5: THRA IHC (bottom) and mRNA (top) 
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Figure 6: DIO3 IHC (bottom) and mRNA (top) 
 
Metals to Thyroid Hormone Regulatory Proteins 
Correlation and significance between the metals and the thyroid hormone regulatory proteins are 
shown in Table 5 with p-values lower than 0.05 indicating significance and correlation (r) values 
higher than approximately 0.6 indicating correlation. Based on these standards, there are no 
significant associations or correlations between metals and thyroid hormone regulatory proteins.  
Table 5: Spearman Correlation and p-values for Metals to Protein Relationship in Placenta 
r-value  
(p-value) 
Arsenic Cadmium Chromium Lead Nickel Selenium Vanadium Zinc 
THRA 0.13696 
(0.3994) 
-0.01426 
(0.9304) 
0.09531 
(0.5585) 
0.07655 
(0.6387) 
-0.19268 
(0.2336) 
-0.19268 
(0.2336) 
-0.01914 
(0.9067) 
-0.29250 
(0.0670) 
Dio3 -0.0777 
(0.6338) 
-0.25666 
(0.1099) 
-0.18236 
(0.2600) 
-0.15929 
(0.3262) 
-0.15816 
(0.3297) 
-0.04071 
(0.8030) 
-0.17261 
(0.2868) 
-0.11332 
(0.4863) 
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Relationship between Placental Cadmium, Zinc, THRA Protein and DIO3 Protein Levels 
There was a negative trend between cadmium levels and THRA protein expression (β= -1.18, 
95% CI -4.32 to 1.97) in pre-eclamptic cases, whereas in normotensive placentas the trend was 
positive (β= 0.42, 95% CI 0.99 to 1.84) (Table 5). There was a negative trend between zinc 
levels and THRA protein expression in preeclamptic and normotensive placentas (β= -0.0021, 
95% CI -0.0083 to 0.0041; β= -0.0005, 95% CI -0.0020 to 0.0010, respectively) (Table 5). The 
trend between DIO3 expression and cadmium was negative in both preeclamptic and 
normotensive placentas, with preeclamptic placentas (β= -3.5, 95% CI -8.1 to 1.1) lower than 
normotensive placentas (β= -1.7, 95% CI -5.3 to 1.9) (Table 5). Trends between DIO3 
expression and placental zinc levels were negative in both preeclamptic and normotensive 
placentas, with preeclamptic placentas (β= -0.0079, 95% CI -0.017 to 0.011) showing a greater 
decrease compared to controls (β= -0.0010, 95% CI -0.0050 to 0.0030) (Table 5).  
Discussion 
 Pre-eclampsia is a disorder that occurs during pregnancy, which results in high urine 
protein content and high blood pressure as symptoms after 20 weeks of pregnancy. It can have 
fatal results for both the mother and the fetus if the placenta is not removed from the body [1]. 
There is no current cure for pre-eclampsia, but it has been linked to problems with the placenta 
[3]. To address this problem, we look at a pilot study of samples from UNC Hospitals called the 
MATT cohort to examine the effects of toxic metal exposure on the thyroid hormone regulatory 
system. The aim of this study was to investigate the effects of toxic metals on Thyroid Hormone 
Receptor Alpha (THRA) and diodinase, iodothyronine type 3 (DIO3), which are associated with 
thyroid hormone function and placenta placement. Previous studies have focused on serum 
samples, and this experiment utilizes placental tissue, which may shed light on the development 
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of pre-eclampsia. The cohort selected provided an even distribution of case and controls to 
compare exposure levels to toxic metals and the occurrence of pre-eclampsia. By investigating 
this relationship, we are better able to understand the biological processes underlying the 
development of pre-eclampsia and supports the theory backing the importance of placenta 
placement in pre-eclampsia cases.  
Few studies have been done to examine thyroid hormone regulation and toxic metal 
interaction in blood samples. Our findings with placental tissue are summarized in Figure 7.  
Figure 7: Model of Interaction between Toxic metals and Thyroid Hormone Regulation 
 
In our trial study, we found significant decreases in zinc, increases in THRA protein levels, and 
decreases in DIO3 protein and gene levels in pre-eclampsia cases. Additionally, there is a 
significant association and positive correlation between zinc and cadmium.  
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This study utilized placental tissue from healthy normotensive and pre-eclamptic women 
to measure relationships between cadmium and zinc levels and thyroid hormone signaling factors 
THRA and DIO3. We found a novel, positive correlation between cadmium and zinc levels in 
pre-eclamptic placentas, and showed that placental zinc levels are lower in preeclampsia 
compared to normotensive women. We also demonstrated that placental THRA protein 
expression was elevated in pre-eclampsia and a modest positive correlation exists between 
placental cadmium level and THRA protein expression in healthy placentas, suggesting an 
underlying possible relationship by which cadmium is a mediator of THRA expression. 
However, in pre-eclamptic cases there was an inverse trend between cadmium and THRA.  
The results of the present study demonstrated a significant association and a positive 
correlation between cadmium and zinc. Additionally, there was a significant decrease in zinc in 
pre-eclampsia cases. This finding is supported by previous studies where zinc has been shown to 
be an important metal in placental development, and higher levels of zinc are associated with 
lower rates of gestational hypertension [10]. Zinc deficiency has also been associated with pre-
eclampsia in previous reports [31]. Cadmium and zinc are chemically similar, which allows 
cadmium to bind to zinc binding sites in the body such as sites related to THRA binding [16, 21]. 
This suggests that the cadmium exposure could prevent zinc from facilitating the binding of 
THRA, which is important for the inactivation of thyroid hormones to ensure correct placental 
development [18, 19]. Interestingly, while we demonstrate a clear association between placental 
cadmium and zinc levels in pre-eclampsia, there was not a statistically significant difference in 
cadmium levels between controls and cases. We report total mean placental cadmium levels of 
4.3ng/g, which is within the lower range of placental cadmium levels previously reported, which 
range from 1.2 to 53ng/g [32]. Studies examining the relationship between cadmium levels and 
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pre-eclampsia are limited, and the results varied [11], despite the body of research demonstrating 
the reproductive and developmental toxicity of cadmium [33]. To our knowledge, we are the first 
to present significant associations between placental cadmium and zinc levels in pre-eclampsia.  
 Our data shows that there is a significant THRA protein expression but a significant 
decrease in DIO3 gene expression in pre-eclampsia cases. In previous studies, DIO3 has been 
found at relatively high levels in the placenta during pregnancy [19]. DIO3 functions to 
inactivate the thyroid hormone thiiodothyronine (T3), which functions by binding to THRA [18, 
19]. The decline in DIO3 could potentially explain the increase in THRA protein expression, 
since it is no longer inactivating the thyroid hormones that are essential in regulating placental 
formation. The elevated placental THRA protein expression in pre-eclampsia cases could 
potentially serve as a biomarker for pre-eclampsia. Interestingly, a modest positive correlation 
exists between cadmium and THRA protein expression in healthy placentas, suggesting an 
underlying mechanism by which cadmium is a mediator in THRA expression. However, in pre-
eclamptic cases, there was an inverse trend between cadmium and THRA. These results suggest 
a dynamic relationship between toxic, environmentally ubiquitous metals and nutritionally 
essential metals and expression of thyroid hormone signaling factors.  
In the present study we prioritized analysis on two key players in thyroid hormone 
signaling, namely THRA and DIO3. Zinc regulates thyroid target gene transcription through 
THRA, and DIO3 expression is regulated by THRA, which ultimately controls T3 levels. 
Moreover, cadmium affects transcription through the activation of metal responsive elements 
(MRE) as well as displacing zinc and altering zinc-mediated transcription and translation, which 
could impact thyroid hormone signaling [28,29]. This study highlights the differential 
relationship between cadmium and THRA expression between pre-eclamptics and controls. This 
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novel study examined the relationships between thyroid hormone signaling regulation and 
cadmium in the context of adverse pregnancy outcomes. The results from this study contributes 
to the existing literature that is aimed at elucidating potential links between the environment and 
placental health.  
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Supplemental 
Table 1: Demographics of MATT Cohort, Chapel Hill, NC 2013 
Characteristic Control Case Overall 
N=20 N=20 N=40 
Race (No., %)    
Caucasian 7 (35.00%) 6 (30.00%) 13 (32.50%) 
African American 6 (30.00%) 9 (45.00%) 15 (37.50%) 
Asian 2 (10.00%) 0 (0.00%) 2 (5.00%) 
Hispanic 5 (25.00%) 2 (10.00%) 7 (17.50%) 
Other 0 (0.00%) 3 (15.00%) 3 (7.50%) 
Age (Mean+/std, 
Median, Range) 
28.35+/-5.49, 28.5, 
(19-38) 
28.15+/-5.6, 28.5, 
(19-37) 
28.25+/-5.48, 28.5, 
(19-38) 
Smoking Status 1 (5.0%) 2 (10.0%) 3 (7.5%) 
Primipara 11 (55.0%) 13 (65.0%) 24 (60.0%) 
Multipara 9 (45.0%) 7 (35.0%) 16 (40.0%) 
Gestational Age 38.6 + 1.9 32.7 + 4.7 35.6 + 4.6 
Placental Weight (mg) 161.2 + 30.6 178.2 + 34.2 169.7 + 33.2 
 
 
